Continuous Gluscose Monitoring Device - Pre Market

NOT DISCLOSED, California

Asking Price $5,000,000 Year Established 2013
Annual Revenue Reason for Selling Needs home with industry appropirate buyer  
Annual P/L Attention Linnea Westlake
Annual Cash Flow Listing Number 540106  
# of Employees Business Category Services: Medical, Dental

Business Overview:

Continuous Gluscose Monitoring Device - Pre Market Asset Sale

Wearable Glucose Sensor - Continuous Glucose Monitor. Company founded in 2013. About $10M invested. Patent pending technology intends to provide highest value and accuracy with lowest sensor drift. It is the foundational technology for the artificial pancreas. With 23.1 million diagnosed and an estimated 7.2 million undiagnosed diabetics in the US and 422 million worldwide (WHO, 2014), continuous, prick free monitoring will offer patients and their doctors painless affordable continuous data to monitor and even potentially reverse the disease in pre-diabetic and Type II diabetics. 1st round of clinical trials have been completed following patent filing and extensive research but it's not past risk threshold yet. Continuous Gluscose Monitoring adoption currently represents about 7% of the market but it is expected to grow to perhaps 34% by 2026 with an affordable alternative. Research and Development is based in So, CA and the next trial is planned for October 2021 collect data to validate accuracy. Down payment $5,000,000 with balance dependent upon structure..

Property Features and Assets:

Market Competition and Expansion:

Additional Details:

  • The property is Leased.
  • The owner is willing to train/assist the new owner.
  • This is not homebased business opportunity.
  • This is not a franchise resale opportunity

Click to Print This Page